Royalty Pharma (RPRX) Long-Term Investments (2019 - 2026)

Royalty Pharma has disclosed Long-Term Investments across 8 years of filings, most recently posting $372.1 million for Q2 2026.

• In Q2 2026, Long-Term Investments rose 34.86% year-over-year to $372.1 million; the TTM figure through Jun 2026 stood at $372.1 million (up 34.86% YoY), while the FY2025 annual figure was $419.0 million, down 39.58% from the prior year.
• Long-Term Investments came in at $372.1 million for Q2 2026 at Royalty Pharma, down from $406.8 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $693.5 million in Q4 2024 to a low of $275.9 million in Q2 2025.
• Average Long-Term Investments over 5 years is $432.7 million, with a median of $408.3 million recorded in 2022.
• Year-over-year, Long-Term Investments surged 73.76% in 2024 and sank 56.2% in 2025.
• Over 5 years, Long-Term Investments stood at $397.2 million in 2022, then gained by 10.05% to $437.1 million in 2023, then soared by 58.66% to $693.5 million in 2024, then sank by 39.58% to $419.0 million in 2025, then decreased by 11.19% to $372.1 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $372.1 million in Q2 2026, $406.8 million in Q1 2026, and $419.0 million in Q4 2025.